Phase 3 Study of Dexpramipexole in ALS - Full Text View

Purpose

The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of Amyotrophic Lateral Sclerosis (ALS).

Condition	Intervention	Phase
Amyotrophic Lateral Sclerosis	Drug: Dexpramipexole Drug: Placebo	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis

Resource links provided by NLM:

Genetics Home Reference related topics: amyotrophic lateral sclerosis

MedlinePlus related topics: Amyotrophic Lateral Sclerosis

Drug Information available for: Pramipexole dihydrochloride Pramipexole

Genetic and Rare Diseases Information Center resources: Amyotrophic Lateral Sclerosis

U.S. FDA Resources

Further study details as provided by Knopp Biosciences:

Primary Outcome Measures:

A joint rank of functional outcomes adjusted for mortality. [ Time Frame: 12 months ]

Secondary Outcome Measures:

Time to death or respiratory insufficiency [ Time Frame: 18 months ]
Time to death [ Time Frame: 18 months ]
Respiratory decline: time to reach less than or equal to 50% of predicted upright slow vital capacity (SVC) or death [ Time Frame: 18 months ]
Change in muscle strength measurements (MSM), as determined by the overall megascore for hand-held dynamometry (HHD) [ Time Frame: 12 months ]
Change in ALS-related health quality, as measured by change in the total score on the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5-Item Form (ALSAQ-5) [ Time Frame: 12 months ]
Population pharmacokinetics. [ Time Frame: 18 months ]
Incidence of adverse events, serious adverse events. [ Time Frame: 18 Months ]


Enrollment:	943
Study Start Date:	March 2011
Study Completion Date:	November 2012
Primary Completion Date:	November 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Dexpramipexole	Drug: Dexpramipexole Oral tablet 150mg twice daily for up to 18 months. Other Name: BIIB050
Placebo Comparator: Placebo	Drug: Placebo Oral tablet twice daily for up to 18 months.

Detailed Description:

Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive, degenerative disease of motor neurons in the brain and spinal cord that leads to muscle atrophy and spasticity in limb and bulbar muscles resulting in weakness and loss of ambulation, oropharyngeal dysfunction, weight loss, and ultimately respiratory failure. The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of ALS.

Eligibility


Ages Eligible for Study:	18 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Aged 18 to 80 years old, inclusive, on Day 1.
Diagnosis of sporadic or familial ALS.
Onset of first ALS symptoms within 24 months prior to Day 1.
World Federation of Neurology El Escorial criteria are met for a possible, laboratory-supported probable, probable, or definite ALS diagnosis.
Upright slow vital capacity (SVC) of 65% or more at screening.
Patients taking or not taking Riluzole are eligible for this study: if a patient has never taken Riluzole, he or she is eligible; if a patient is currently taking Riluzole, he or she must have been on a stable dose for at least 60 days; if a patient has discontinued Riluzole, he or she must have stopped taking it for at least 30 days.
Must be able to swallow tablets at the time of study entry.

Exclusion Criteria:

Other medically significant illness.
Clinically significant abnormal laboratory values.
Pregnant women or women breastfeeding.
Prior exposure to dexpramipexole.
Currently taking pramipexole or other dopamine agonists.

Other protocol-defined inclusion/exclusion criteria may apply.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01281189

Show 82 Study Locations

Sponsors and Collaborators

Knopp Biosciences

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA; EMPOWER investigators. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013 Nov;12(11):1059-67. doi: 10.1016/S1474-4422(13)70221-7. Epub 2013 Sep 23. Erratum in: Lancet Neurol. 2013 Nov;12(11):1042. Carbonell, J G [corrected to Gamez, J].


Responsible Party:	Knopp Biosciences
ClinicalTrials.gov Identifier:	NCT01281189 History of Changes
Other Study ID Numbers:	223AS302 EUDRA CT NO: 2010-022818-19
Study First Received:	January 20, 2011
Last Updated:	November 24, 2014

Keywords provided by Knopp Biosciences:


Amyotrophic Lateral Sclerosis ALS Motor Neurone Disease

Additional relevant MeSH terms:


Sclerosis Motor Neuron Disease Amyotrophic Lateral Sclerosis Pathologic Processes Neurodegenerative Diseases Nervous System Diseases Neuromuscular Diseases Spinal Cord Diseases Central Nervous System Diseases TDP-43 Proteinopathies Proteostasis Deficiencies	Metabolic Diseases Pramipexole Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Antiparkinson Agents Anti-Dyskinesia Agents Dopamine Agonists Dopamine Agents Neurotransmitter Agents

ClinicalTrials.gov processed this record on June 22, 2017

Phase 3 Study of Dexpramipexole in ALS (EMPOWER)